LEXINGTON, Ky. (July 11, 2019) — Faculty from the University of Kentucky Department of Psychology in the College of Arts and Sciences and the Department of Behavioral Science in the College of Medicine have received two, five-year Research Project Grants (R01) from the National Institutes of Health (NIH) to study neurobehavioral processes involved in drug use disorders.
The first project, which addresses cocaine use disorder, totals over $3 million. The second project addresses opioid use disorder and totals over $3.1 million.
The multiple principal investigators (PI) include Joshua Beckmann, associate professor of psychology; Joshua Lile, professor of behavioral science; and Michael Wesley, assistant professor of behavioral science and director of the UK Neurobehavioral Systems Lab. The three PIs also have joint appointments in the College of Arts and Sciences' neuroscience program.
Cocaine and opioid use disorders are characterized by ongoing decisions to pursue and use drugs over other available activities and goods. However, the decision-making processes that underlie the choice to use these drugs is not well understood. To determine why and how a decision is made, it is necessary to replicate dynamic, real-life environments in which the outcome of decisions is uncertain. But according to Beckmann, research to date is predicated upon testing conditions that minimize the complexity of the context in which these choices occur, and consequently, the decision-making processes.
"Existing literature tells us that choice is dynamic and largely context-dependent," Beckmann said. "Thus, in order to better understand how decision-making and choice contribute to substance use disorder, we are developing and utilizing multidisciplinary tools to represent and capture the dynamics of drug use decisions and associated processes.”
By using a technique known as probabilistic reinforcement learning choice procedure, along with computational data modeling and neuroimaging/neuromodulation/neurorecording techniques, the researchers will reveal neurobehavioral processes underlying suboptimal choice.
And while the projects have a similar theoretical basis and use overlapping methodologies, the researchers noted the two will involve some important differences. Specifically, the cocaine use disorder project will use established interventions, such as agonist replacement medication and large financial alternatives, to examine mechanisms by which behavior is reallocated away from cocaine use. The opioid use disorder project is more focused on how withdrawal drives continued opioid use.
“Modeling drug-use decisions under more real-world conditions is important because decision-making in dynamic, uncertain environments has been shown to alter the value of competing choice options, and requires continuous updating of option values, which engages neurobehavioral processes that might be functioning abnormally in substance use disorder,” Lile said.
The team emphasized that substance use disorder is highly complex, and the field should strive to continuously adapt its laboratory procedures to more accurately model the features of the condition.
“We believe that our approach is a valuable step forward that will improve our understanding of drug-use decisions and advance the development of improved treatments,” Lile said.
According to Wesley, the projects are in line with both national and university initiatives to enhance translational and team science.
"These projects integrate our expertise in advanced and diverse methodologies applied simultaneously to preclinical and clinical research, which should minimize the time between scientific discovery and clinical benefit," he said. "By working together, we offer a better return on investment compared to more typical and diffuse operations. Our coordinated scientific efforts represent an agile, efficient and innovative approach to quantifying the dynamic nature of decision-making and choice in substance use disorder.”
“Years of research suggest that substance use disorder is a multifaceted condition; as such, our multidisciplinary approach aims to better understand the multiple facets of substance use disorder and how they interact, with the hope of developing improved treatment strategies,” Beckmann said.
The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity and INSIGHT into Diversity recognized us as a Diversity Champion two years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. The Chronicle of Higher Education judged us a “Great College to Work for,” and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers." We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for three straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.